^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    azenosertib (ZN-c3)

    i
    Other names: ZN-c3, ZN c3, ZNc3
    Company:
    Zentalis Pharma
    Drug class:
    WEE1 inhibitor
    Related drugs:
    7d
    DENALI: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=310, Recruiting, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | N=170 --> 310
    Enrollment change • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CCNE1 (Cyclin E1) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    azenosertib (ZN-c3)
    15d
    ZN-c3-002: A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer (clinicaltrials.gov)
    P1, N=172, Recruiting, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Trial completion date: Feb 2027 --> Jun 2028 | Trial primary completion date: Dec 2024 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • azenosertib (ZN-c3)
    19d
    ZN-c3-003: A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma (clinicaltrials.gov)
    P1, N=31, Completed, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase classification: P1/2 --> P1
    Phase classification
    |
    gemcitabine • azenosertib (ZN-c3)
    1m
    TETON: A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma (clinicaltrials.gov)
    P2, N=92, Completed, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Recruiting --> Completed | Trial completion date: May 2025 --> Oct 2025 | Trial primary completion date: Nov 2024 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 positive
    |
    azenosertib (ZN-c3)
    1m
    ZN-c3-003: A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma (clinicaltrials.gov)
    P1/2, N=31, Completed, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Active, not recruiting --> Completed | N=84 --> 31
    Trial completion • Enrollment change
    |
    gemcitabine • azenosertib (ZN-c3)
    1m
    MAMMOTH: A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=117, Completed, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jan 2026 | Trial primary completion date: May 2025 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date • Platinum resistant
    |
    Zejula (niraparib) • azenosertib (ZN-c3)
    1m
    ZN-c3-001: A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=274, Completed, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Recruiting --> Completed | N=146 --> 274 | Trial completion date: Aug 2023 --> May 2025 | Trial primary completion date: May 2023 --> May 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    azenosertib (ZN-c3)
    1m
    Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open
    |
    CCNE1 (Cyclin E1)
    |
    HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • azenosertib (ZN-c3)
    2ms
    Azenosertib in Uterine Serous Carcinoma: Biomarker Study (clinicaltrials.gov)
    P2, N=25, Recruiting, Joyce Liu, MD | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR
    |
    azenosertib (ZN-c3)
    3ms
    Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors (clinicaltrials.gov)
    P1, N=48, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    CCNE1 (Cyclin E1)
    |
    HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • azenosertib (ZN-c3)
    3ms
    ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC (clinicaltrials.gov)
    P1/2, N=78, Active, not recruiting, Filipa Lynce, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • azenosertib (ZN-c3)
    8ms
    ZN-c3-016: ZN-c3 in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=44, Terminated, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Trial completion date: Sep 2026 --> Jul 2025 | Active, not recruiting --> Terminated; Study terminated due to change in therapeutic landscape.
    Trial completion date • Trial termination
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • azenosertib (ZN-c3)